Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
- Status
- RECRUITING
- Phase
- PHASE3
A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE1
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- Status
- RECRUITING
- Phase
- PHASE3
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- Status
- RECRUITING
- Phase
- PHASE2
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1